JP2013079270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013079270A5 JP2013079270A5 JP2012282406A JP2012282406A JP2013079270A5 JP 2013079270 A5 JP2013079270 A5 JP 2013079270A5 JP 2012282406 A JP2012282406 A JP 2012282406A JP 2012282406 A JP2012282406 A JP 2012282406A JP 2013079270 A5 JP2013079270 A5 JP 2013079270A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- formulation
- vegf
- histidine
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66512505P | 2005-03-25 | 2005-03-25 | |
| US60/665,125 | 2005-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Division JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013079270A JP2013079270A (ja) | 2013-05-02 |
| JP2013079270A5 true JP2013079270A5 (enExample) | 2013-11-14 |
| JP5752671B2 JP5752671B2 (ja) | 2015-07-22 |
Family
ID=36678320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Active JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
| JP2012282406A Active JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Active JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US20060217311A1 (enExample) |
| EP (3) | EP1861116B1 (enExample) |
| JP (2) | JP5376573B2 (enExample) |
| KR (1) | KR101327270B1 (enExample) |
| CN (2) | CN102614134B (enExample) |
| AU (1) | AU2006229930C1 (enExample) |
| CA (3) | CA3142945A1 (enExample) |
| CY (2) | CY1116980T1 (enExample) |
| DK (2) | DK2586459T3 (enExample) |
| ES (2) | ES2548238T3 (enExample) |
| HU (2) | HUE027096T2 (enExample) |
| IL (2) | IL185606A (enExample) |
| LT (1) | LT2586459T (enExample) |
| NZ (1) | NZ560713A (enExample) |
| PL (2) | PL1861116T3 (enExample) |
| PT (2) | PT2586459T (enExample) |
| SI (2) | SI1861116T1 (enExample) |
| WO (1) | WO2006104852A2 (enExample) |
| ZA (1) | ZA200708845B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| US7572893B2 (en) * | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| RU2432155C3 (ru) * | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| AU2012202859C1 (en) * | 2006-06-16 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| EP2612867A1 (en) | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| WO2010060748A1 (en) * | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| JP5918246B2 (ja) | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 |
| CN102552875B (zh) * | 2010-12-09 | 2015-05-20 | 上海国健生物技术研究院 | 一种双功能vegf受体融合蛋白制剂 |
| MX385629B (es) | 2011-01-13 | 2025-03-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. |
| EP2696851B1 (en) * | 2011-04-14 | 2022-06-08 | The Regents of The University of California | Multilayer thin film drug delivery device |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| PT3574897T (pt) | 2011-11-18 | 2022-04-06 | Regeneron Pharma | Formulação de libertação prolongada compreendendo micropartículas de proteína polimérica para utilização no vítreo do olho para o tratamento de distúrbios oculares vasculares |
| NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| RU2664473C2 (ru) * | 2012-03-16 | 2018-08-17 | Регенерон Фармасьютикалз, Инк. | ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ |
| AR092325A1 (es) * | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
| HK1206628A1 (en) * | 2012-08-02 | 2016-01-15 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN103110105A (zh) * | 2012-11-14 | 2013-05-22 | 江苏江山制药有限公司 | 食品添加剂无糖维生素c钠盐颗粒的生产方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| CN104940926B (zh) * | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| BR112017014376A2 (en) | 2015-01-28 | 2018-05-02 | Pfizer Inc. | stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| PL3384049T3 (pl) | 2015-12-03 | 2024-01-22 | Regeneron Pharmaceuticals, Inc. | Sposoby powiązania wariantów genetycznych z wynikiem klinicznym u pacjentów cierpiących na zwyrodnienie plamki związane z wiekiem, leczonych anty-vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3407868A1 (en) * | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| MY197672A (en) | 2016-10-07 | 2023-07-03 | Regeneron Pharma | Room temperature stable lyophilized protein |
| EP3541365A1 (en) * | 2016-11-21 | 2019-09-25 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
| USD849856S1 (en) | 2017-06-28 | 2019-05-28 | Jumpsport, Inc. | Standing platform |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| MA50908A (fr) | 2017-11-17 | 2020-09-23 | Amgen Inc | Formulations de protéines de fusion vegfr-fc |
| CN111356471A (zh) | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途 |
| SMT202200374T1 (it) | 2017-11-30 | 2022-11-18 | Regeneron Pharma | Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio |
| WO2019124946A1 (ko) * | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
| ES3009668T3 (en) | 2018-01-26 | 2025-03-31 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| WO2019173767A1 (en) | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| EP4065150A4 (en) | 2019-11-25 | 2023-12-06 | The Regents of the University of California | LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION |
| KR20230152810A (ko) | 2019-12-06 | 2023-11-03 | 리제너론 파아마슈티컬스, 인크. | 항-vegf 단백질 조성물 및 이를 생산하는 방법 |
| KR102337471B1 (ko) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| US20230312683A1 (en) * | 2020-07-31 | 2023-10-05 | Celltrion Inc. | Stable pharmaceutical preparation |
| WO2025140553A1 (zh) * | 2023-12-27 | 2025-07-03 | 成都康弘生物科技有限公司 | 一种含有抗vegf的融合蛋白的药物组合物 |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| SI1516628T1 (sl) * | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) * | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JPH10273450A (ja) | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| NZ514488A (en) | 1999-04-16 | 2004-01-30 | Genentech Inc | Vascular endothelial cell growth factor variants and uses thereof |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| DK1478394T3 (da) | 2002-02-27 | 2008-10-13 | Immunex Corp | Stabiliseret TNFR-Fc formulation med arginin |
| AU2004226417B2 (en) * | 2003-03-28 | 2009-01-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
| DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| WO2004103159A2 (en) * | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| ITMI20031261A1 (it) | 2003-06-20 | 2004-12-21 | Messersi Packaging Srl | Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia. |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050112061A1 (en) | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| SI1660057T1 (sl) | 2003-08-27 | 2012-10-30 | Ophthotech Corp | Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| EP1732947B1 (en) | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
| EP1740168A2 (en) | 2004-04-21 | 2007-01-10 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| KR100897379B1 (ko) | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| US7354580B2 (en) | 2004-06-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| AU2005265071A1 (en) | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| EP2324848A3 (en) | 2004-10-21 | 2011-09-14 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| AU2006214658A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| RU2432155C3 (ru) | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| PE20170142A1 (es) | 2014-01-25 | 2017-04-02 | Chengdu Kanghong Biotechnologies Co Ltd | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2006
- 2006-03-22 CN CN201210090068.4A patent/CN102614134B/zh active Active
- 2006-03-22 PL PL06748594T patent/PL1861116T3/pl unknown
- 2006-03-22 HU HUE06748594A patent/HUE027096T2/en unknown
- 2006-03-22 LT LTEP13152402.7T patent/LT2586459T/lt unknown
- 2006-03-22 PL PL13152402T patent/PL2586459T3/pl unknown
- 2006-03-22 CN CN2006800085696A patent/CN101141975B/zh active Active
- 2006-03-22 CA CA3142945A patent/CA3142945A1/en active Pending
- 2006-03-22 KR KR1020077024202A patent/KR101327270B1/ko active Active
- 2006-03-22 ES ES06748594.6T patent/ES2548238T3/es active Active
- 2006-03-22 HU HUE13152402A patent/HUE034109T2/en unknown
- 2006-03-22 EP EP06748594.6A patent/EP1861116B1/en active Active
- 2006-03-22 CA CA2598711A patent/CA2598711C/en active Active
- 2006-03-22 ES ES13152402.7T patent/ES2633574T3/es active Active
- 2006-03-22 PT PT131524027T patent/PT2586459T/pt unknown
- 2006-03-22 US US11/387,256 patent/US20060217311A1/en not_active Abandoned
- 2006-03-22 JP JP2008503191A patent/JP5376573B2/ja active Active
- 2006-03-22 ZA ZA200708845A patent/ZA200708845B/xx unknown
- 2006-03-22 SI SI200631996T patent/SI1861116T1/sl unknown
- 2006-03-22 NZ NZ560713A patent/NZ560713A/en unknown
- 2006-03-22 PT PT67485946T patent/PT1861116E/pt unknown
- 2006-03-22 CA CA2995971A patent/CA2995971A1/en active Pending
- 2006-03-22 SI SI200632195T patent/SI2586459T1/sl unknown
- 2006-03-22 AU AU2006229930A patent/AU2006229930C1/en active Active
- 2006-03-22 DK DK13152402.7T patent/DK2586459T3/en active
- 2006-03-22 EP EP13152402.7A patent/EP2586459B1/en active Active
- 2006-03-22 DK DK06748594.6T patent/DK1861116T3/en active
- 2006-03-22 WO PCT/US2006/010600 patent/WO2006104852A2/en not_active Ceased
- 2006-03-22 EP EP17159239.7A patent/EP3195874A1/en not_active Ceased
-
2007
- 2007-08-30 IL IL185606A patent/IL185606A/en active IP Right Grant
-
2010
- 2010-07-13 US US12/835,065 patent/US8110546B2/en active Active
-
2012
- 2012-01-04 US US13/343,214 patent/US8404638B2/en active Active
- 2012-03-23 US US13/428,510 patent/US8710004B2/en active Active
- 2012-12-26 JP JP2012282406A patent/JP5752671B2/ja active Active
-
2013
- 2013-06-04 US US13/909,745 patent/US8921316B2/en active Active
- 2013-06-27 IL IL227215A patent/IL227215A/en active IP Right Grant
-
2014
- 2014-11-21 US US14/550,385 patent/US9416167B2/en active Active
-
2015
- 2015-11-26 CY CY20151101068T patent/CY1116980T1/el unknown
-
2016
- 2016-03-08 US US15/064,343 patent/US9511140B2/en active Active
- 2016-05-10 US US15/150,840 patent/US9636400B2/en not_active Expired - Fee Related
- 2016-11-03 US US15/342,989 patent/US20170073407A1/en not_active Abandoned
-
2017
- 2017-08-02 CY CY20171100827T patent/CY1119243T1/el unknown
- 2017-08-31 US US15/692,893 patent/US10406226B2/en active Active
-
2019
- 2019-08-08 US US16/535,610 patent/US10857231B2/en active Active
-
2020
- 2020-11-17 US US16/950,584 patent/US11806398B2/en active Active
-
2021
- 2021-05-04 US US17/307,240 patent/US20210252147A1/en not_active Abandoned
- 2021-05-05 US US17/308,801 patent/US20210252105A1/en not_active Abandoned
- 2021-05-06 US US17/313,627 patent/US20210393778A1/en not_active Abandoned
- 2021-05-07 US US17/314,992 patent/US20210393530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013079270A5 (enExample) | ||
| JP2009540001A5 (enExample) | ||
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| JP2016520075A5 (enExample) | ||
| RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
| JP2015231997A5 (enExample) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| MX374287B (es) | Formulacion que contiene virus y uso de la misma. | |
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| JP2009292810A5 (enExample) | ||
| JP2014508734A5 (enExample) | ||
| JP2012515221A5 (enExample) | ||
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| FI3725330T3 (fi) | Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset | |
| CN102580062B (zh) | 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂 | |
| CN102727903B (zh) | 一种高致病性猪繁殖与呼吸综合征活疫苗jxa1-r株耐热冻干保护剂及制备方法 | |
| JP2016534052A5 (enExample) | ||
| RU2016105462A (ru) | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства | |
| JP2008510716A5 (enExample) | ||
| HRP20190954T1 (hr) | Stabilne formulacije imunoglobulinskih jednostrukih varijabilnih domena i njihove uporabe | |
| AU2008225501B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| RU2016131667A (ru) | Состав препарата нейрегулина | |
| RU2017125931A (ru) | Фармацевтическая композиция, содержащая плазминоген, и ее применение | |
| JP2012136518A5 (enExample) | ||
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |